161 related articles for article (PubMed ID: 38611061)
1. Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis.
Nguyen L; Saha A; Kuykendall A; Zhang L
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611061
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract][Full Text] [Related]
3. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
4. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
5. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
7. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
Valent P; Klion AD; Roufosse F; Simon D; Metzgeroth G; Leiferman KM; Schwaab J; Butterfield JH; Sperr WR; Sotlar K; Vandenberghe P; Hoermann G; Haferlach T; Moriggl R; George TI; Akin C; Bochner BS; Gotlib J; Reiter A; Horny HP; Arock M; Simon HU; Gleich GJ
Allergy; 2023 Jan; 78(1):47-59. PubMed ID: 36207764
[TBL] [Abstract][Full Text] [Related]
8. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.
Valent P; Degenfeld-Schonburg L; Sadovnik I; Horny HP; Arock M; Simon HU; Reiter A; Bochner BS
Semin Immunopathol; 2021 Jun; 43(3):423-438. PubMed ID: 34052871
[TBL] [Abstract][Full Text] [Related]
9. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
10. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
11. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
12. The Diagnostic Work-Up of Hypereosinophilia.
Wang SA
Pathobiology; 2019; 86(1):39-52. PubMed ID: 29961056
[TBL] [Abstract][Full Text] [Related]
13. Causes of hypereosinophilia in 100 consecutive patients.
Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC
Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630
[TBL] [Abstract][Full Text] [Related]
14. (A Critical Appraisal of) Classification of Hypereosinophilic Disorders.
Kahn JE; Groh M; Lefèvre G
Front Med (Lausanne); 2017; 4():216. PubMed ID: 29259972
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
Iurlo A; Cattaneo D
Blood Rev; 2023 Mar; 58():101014. PubMed ID: 36153195
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes.
Stella S; Massimino M; Manzella L; Pennisi MS; Tirrò E; Romano C; Vitale SR; Puma A; Tomarchio C; Gregorio SD; Palumbo GA; Vigneri P
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418988
[TBL] [Abstract][Full Text] [Related]
17. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract][Full Text] [Related]
18. Updates on eosinophilic disorders.
Tzankov A; Reichard KK; Hasserjian RP; Arber DA; Orazi A; Wang SA
Virchows Arch; 2023 Jan; 482(1):85-97. PubMed ID: 36068374
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic myeloid neoplasms.
Noel P; Mesa RA
Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
[TBL] [Abstract][Full Text] [Related]
20. Approach to the patient with suspected hypereosinophilic syndrome.
Klion AD
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):47-54. PubMed ID: 36485140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
